tbuckley/cabot-search huggingface dataset:
Seven-Year (yr) Follow-up of Patients (pts) with Imatinib-Resistant or -Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Receiving Dasatinib in Study CA180-034, Final Study Results
Authors: Neil P. Shah, Philippe Rousselot, Charles A. Schiffer, Delphine Rea, Jorge E. Cortes, Jorge Milone, Hesham Mohamed, Diane Healey, Hagop Kantarjian, Andreas Hochhaus, Giuseppe Saglio
Journal: Blood (2014)
Molecular Cytogenetic Studies of Complex Karyotypes in Myelodysplastic Syndromes (MDS): Conventional Cytogenetics, FISH and Multiplex FISH (mFISH/mBAND)
Authors: Zuzana Zemanova, Kyra Michalova, Jana Brezinova, Libuse Lizcova, Silvia Izakova, Magda Siskova, Olga Cerna, Jaroslav Cermak
Journal: Blood (2008)
TCT-251 Impact of obesity on in-hospital mortality and 1-year clinical outcome in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Results from INTERSTELLAR registry
Authors: Pyung Chun Oh, Woong Chol Kang, Jeonggeun Moon, Jon Suh, Hyun Woo Park, Ho-Jun Jang, Tae-Hoon Kim, Sang-Don Park, Sung Woo Kwon, Taehoon Ahn, Eak Kyun Shin
Journal: Journal of the American College of Cardiology (2015)
Comparison of Two Induction Regimens, High Dose Cytarabine /Mitoxantrone vs Hyper-CVAD, for Adult Acute Lymphoblastic Leukemia/Lymphoma.
Authors: Woondong Jeong, Delong Liu, Sreedhar Katragadda, Qiuhu Shi, Tauseef Ahmed, Karen Seiter
Journal: Blood (2005)
Announcing the New JAMASurgery.com
Authors: Paul Gee, Colleen Kelly, Michael Berkwits
Journal: JAMA Surgery (2016)

This week, JAMA Surgery and The JAMA Network launch a new online platform at jamasurgery.com.We have cocreated the sites with you-our users-combining data about how the sites are used with extensive input from clinician and author colleagues to redesign every page focusing on our mosttrafficked article pages.We have aimed to make the platform more usable, discoverable, and faster on any device.Here are some highlights:
Detection of anti-drug antibodies (ADAs) reactive with trastuzumab in HER2-positive breast cancer patients treated with trastuzumab.
Authors: Paula Raffin Pohlmann, Steve Simmons, Jennifer Baker, Lori Baucom, Ray Mernaugh, Elliott Dawson
Journal: Journal of Clinical Oncology (2014)

e11567 Background: By itself, native trastuzumab is considered non-immunogenic. However, unfolded/denatured antibodies can elicit an anti-antibody response. We developed an anti-trastuzumab antibody serum test indicative of shorter disease free survival in a small cohort of patients with HER2 positive breast cancer treated with trastuzumab ( Pohlmann PR, M.T., Blum DL. Trastuzumab-reactive antibodies (TR-abs) in serum and trastuzumab (Tzb) benefit prediction in patients with HER2-overexpressing breast cancer. J Clin Oncol 30, Abstract 77 (2012). Aim: To further develop/characterize the multiplex ELISA array prior to prospective validation. Methods: Trastuzumab F(ab’)2and synthetic peptide fragments representing components of trastuzumab, or a HER2 synthetic peptide mimetic, were used. Trastuzumab-treated, HER2 positive breast cancer patient plasma/serum samples (n=34; 22 adjuvant; 12 metastatic) obtained from tissue repositories were analyzed by the multiplex ELISA array. Results: For IgG, 26% (9 of 34) of samples from trastuzumab-treated HER2 positive breast cancer patients had detectable antibodies that reacted with components of trastuzumab in the assay, with an absorbency reading greater than 1.0 OD. Assay performance has been improved by optimizing reaction plate preparation, antigen binding, patient dilution, HRP-labeled secondary antibody source and dilution, and colorimetric signal generation and assay performance temperature (range ~20°C-25°C). Assay linearity was established over the range of 1:50 to 1:400 dilution for serum from a sample yielding >3.4 OD using immobilized trastuzumab F(ab’)2 as antigen and for peptides from 1:50 up to 1:2700 with linear correlation coefficients of R2=0.99. Serum or plasma from same blood draw gave equivalent results. Inter-day and intra-day coefficient of variation were less than 5.0 % for the panel of analytes. Conclusions: We have been able to reproduce the original findings in a different cohort of trastuzumab treated HER2 positive breast cancer patients using an improved multiplexed ELISA array. The assay was found to be reliable and robust and is ready for further clinical development and validation.
Platelets Induce Thymic Stromal Lymphopoietin Production by Endothelial Cells: Contribution to Fibrosis in Human Systemic Sclerosis
Authors: Marie‐Elise Truchetet, Béatrice Demoures, Jorge Eduardo Guimaraes, Anne Bertrand, Paôline Laurent, Valérie Jolivel, Isabelle Douchet, Clément Jacquemin, Liliane Khoryati, Pierre Duffau, Estibaliz Lazaro, Christophe Richez, Julien Seneschal, Marie‐Sylvie Doutre, Jean‐Luc Pellegrin, Joël Constans, Thierry Schaeverbeke, Patrick Blanco, Cécile Contin‐Bordes
Journal: Arthritis & Rheumatology (2016)

To investigate the relationship between vascular damage and fibrosis in systemic sclerosis (SSc) by testing the hypothesis that platelets contribute to skin fibrosis via the activation of human dermal microvascular endothelial cells (HDMECs) and subsequent production of profibrotic mediators.A total of 203 SSc patients and 30 healthy donors were prospectively enrolled between 2012 and 2015 at the University Hospital of Bordeaux. Immunohistochemistry and immunofluorescence analyses were performed on skin biopsy sections from 18 SSc patients and 5 healthy donors. Serum thymic stromal lymphopoietin (TSLP) levels were measured by enzyme-linked immunosorbent assay in the entire cohort. HDMECs and fibroblasts were purified from biopsy sections. Extracellular matrix production by cultured fibroblasts was assessed by real-time quantitative polymerase chain reaction.Serum TSLP levels were significantly increased in SSc patients compared to healthy donors (P < 0.0001) and were associated with a higher frequency of vasculopathy (P = 0.02). The proportion of TSLP-positive dermal cells was increased in the skin of SSc patients compared with healthy donors (P < 0.0001) and was correlated with fibrosis (modified Rodnan skin thickness score) (r = 0.6146, P = 0.0001). In SSc dermis, TSLP was mainly expressed by CD31-positive endothelial cells. In vitro, activated platelets induced TSLP production by HDMECs in an interleukin-1β-dependent manner. SSc fibroblasts responded differently according to their original TSLP environment.Taken together, these results identify HDMECs as contributors to TSLP production in SSc and suggest a potential mechanism by which platelets may profoundly affect the fibrotic process in SSc.
Exercise and pregnancy in recreational and elite athletes: 2016 evidence summary from the IOC expert group meeting, Lausanne. Part 2—the effect of exercise on the fetus, labour and birth
Authors: Kari Bø, Raul Artal, Ruben Barakat, Wendy Brown, Michael Dooley, Kelly R Evenson, Lene A H Haakstad, Karin Larsen, Bengt Kayser, Tarja I Kinnunen, Michelle F Mottola, Ingrid Nygaard, Mireille van Poppel, Britt Stuge, Gregory A L Davies
Journal: British Journal of Sports Medicine (2016)

This is Part 2 of 5 in the series of evidence statements from the IOC expert committee on exercise and pregnancy in recreational and elite athletes. Part 1 focused on the effects of training during pregnancy and on the management of common pregnancy-related symptoms experienced by athletes. In Part 2, we focus on maternal and fetal perinatal outcomes.
TCT-237 Efficacy and Safety of Routine Thrombus Aspiration in Patients with ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: an updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
Authors: Ioannis Mastoris, Gennaro Giustino, Samantha Sartori, Usman Baber, Roxana Mehran, Annapoorna Kini, Samin K. Sharma, George Dangas
Journal: Journal of the American College of Cardiology (2015)
Transcriptome Analysis Reveals That G Protein-Coupled Receptors Are Potential Diagnostic Markers or Therapeutic Targets in Acute Myeloid Leukemia
Authors: Arhamatoulaye Maiga, Sébastien Lemieux, Caroline Pabst, Vincent-Philippe Lavallée, Michel Bouvier, Guy Sauvageau, Josée Hébert
Journal: Blood (2015)
CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways
Authors: Xuejiao Liu, Yulong Chong, Yiming Tu, Ning Liu, Chenglong Yue, Zhenglei Qi, Huize Liu, Yao Yao, Hongmei Liu, Shangfeng Gao, Mingshan Niu, Rutong Yu
Journal: Journal of Hematology & Oncology (2016)

Malignant gliomas are associated with a high mortality rate, and effective treatment options are limited. Thus, the development of novel targeted treatments to battle this deadly disease is imperative.In this study, we investigated the in vitro effects of the novel reversible chromosomal region maintenance 1 (CRM1) inhibitor S109 on cell proliferation in human gliomas. S109 was also evaluated in an intracranial glioblastoma xenograft model.We found that high expression of CRM1 in glioma is a predictor of short overall survival and poor patient outcome. Our data demonstrate that S109 significantly inhibits the proliferation of human glioma cells by inducing cell cycle arrest at the G1 phase. Notably, we observed that high-grade glioma cells are more sensitive to S109 treatment compared with low-grade glioma cells. In an intracranial mouse model, S109 significantly prolonged the survival of tumor-bearing animals without causing any obvious toxicity. Mechanistically, S109 treatment simultaneously perturbed the three core pathways (the RTK/AKT/Foxos signaling pathway and the p53 and Rb1 tumor-suppressor pathways) implicated in human glioma cells by promoting the nuclear retention of multiple tumor-suppressor proteins.Taken together, our study highlights the potential role of CRM1 as an attractive molecular target for the treatment of human glioma and indicates that CRM1 inhibition by S109 might represent a novel treatment approach.
TCT-598 Revascularization strategies for patients with multiple vessel disease and unprotected left main with a cobalt-chromium rapamycin eluting stent (ERACI IV Registry)
Authors: Alfredo M. Rodriguez-Granillo, Juan Mieres, Raul Solerno, Carlos Fernandez-Pereira, Carlos Haiek, Omar Santaera, Ignacio Rifourcat, Miguel Larribau, Alfredo E. Rodriguez
Journal: Journal of the American College of Cardiology (2015)
TCT-746 Transcatheter Alcohol Septal Ablation in Patient with Hypertrophic Obstructive Cardiomyopathy: the Immediate and Long-Term Results
Authors: Stanislav Fanta, Vasyl Lazoryshynets, Evgen Aksenov, Konstantin Rudenko, Natalia Kollyakova, Natalia Yashchuk
Journal: Journal of the American College of Cardiology (2015)
GW27-e1170 Investigation of Mitral Leaflet Elongation in Patients with Non-obstructive and Latent-obstructive Hypertrophic Cardiomyopathy
Authors: Lei Zuo, Jing Wang, Mengyao Zhou, Ruiqi Guo, Nan Kang, Hong Shao, Chao Sun, Liwen Liu
Journal: Journal of the American College of Cardiology (2016)
Brentuximab Vedotin (SGN-35) in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies without Prior High-Dose Chemotherapy and Stem Cell Transplantation.
Authors: Achim Rothe, Stephanie Sasse, Helen Goergen, Dennis A. Eichenauer, Andreas Lohri, Ulrich Jäger, Christopher Bangard, Andreas Engert
Journal: Blood (2012)
Incidental Sclerosing Pneumocytoma Detected on Bone Scintigraphy
Authors: Alex Cheen Hoe Khoo, Fadzilah Hamzah, Choo Khoon Ong
Journal: Clinical Nuclear Medicine (2016)

Nonosseous uptake in Tc-hydroxymethylene bone scintigraphy should always be evaluated for any possibility of pathological changes. We share interesting images of a 60-year-old woman initially investigated for suspected osteomyelitis of the left femur but found to have an extraosseous uptake in the right hemithorax on bone scintigraphy. Plain chest radiograph followed by contrast-enhanced CT of the thorax revealed the presence of a lung mass in the right lower lobe with no lymphadenopathy. CT-guided biopsy yielded fibrocollagenous tissue, partly lined by benign pneumocytes. The F-FDG-avid lung mass was confirmed to be sclerosing pneumocytoma postlobectomy.
Association Between the 2014 Medicaid Expansion and US Hospital Finances
Authors: Fredric Blavin
Journal: JAMA (2016)

<h3>Importance</h3> The Affordable Care Act expanded Medicaid eligibility for millions of low-income adults. The choice for states to expand Medicaid could affect the financial health of hospitals by decreasing the proportion of patient volume and unreimbursed expenses attributable to uninsured patients while increasing revenue from newly covered patients. <h3>Objective</h3> To estimate the association between the Medicaid expansion in 2014 and hospital finances by assessing differences between hospitals in states that expanded Medicaid and in those states that did not expand Medicaid. <h3>Design and Setting</h3> Observational study with analysis of data for nonfederal general medical or surgical hospitals in fiscal years 2011 through 2014, using data from the American Hospital Association Annual Survey and the Health Care Cost Report Information System from the US Centers for Medicare &amp; Medicaid Services. Multivariable difference-in-difference regression analyses were used to compare states with Medicaid expansion with states without Medicaid expansion. Hospitals in states that expanded Medicaid eligibility before January 2014 were excluded. <h3>Exposures</h3> Medicaid expansion in 2014, accounting for variation in fiscal year start dates. <h3>Main Outcomes and Measures</h3> Hospital-reported information on uncompensated care, uncompensated care as a percentage of total hospital expenses, Medicaid revenue, Medicaid as a percentage of total revenue, operating margins, and excess margins. <h3>Results</h3> The sample included between 1200 and 1400 hospitals per fiscal year in 19 states with Medicaid expansion and between 2200 and 2400 hospitals per fiscal year in 25 states without Medicaid expansion (with sample size varying depending on the outcome measured). Expansion of Medicaid was associated with a decline of $2.8 million (95% CI, −$4.1 to −$1.6 million;<i>P</i> &lt; .001) in mean annual uncompensated care costs per hospital. Hospitals in states with Medicaid expansion experienced a $3.2 million increase (95% CI, $0.9 to $5.6 million;<i>P</i> = .008) in mean annual Medicaid revenue per hospital, relative to hospitals in states without Medicaid expansion. Medicaid expansion was also significantly associated with improved excess margins (1.1 percentage points [95% CI, 0.1 to 2.0 percentage points];<i>P</i> = .04), but not improved operating margins (1.1 percentage points [95% CI, −0.1 to 2.3 percentage points];<i>P</i> = .06). <h3>Conclusions and Relevance</h3> The hospitals located in the 19 states that implemented the Medicaid expansion had significantly increased Medicaid revenue, decreased uncompensated care costs, and improvements in profit margins compared with hospitals located in the 25 states that did not expand Medicaid. Further study is needed to assess longer-term implications of this policy change on hospitals’ overall finances.
TCT-410 Results Of Percutaneous Coronary Intervention Of “De Novo” Lesions With Sequent Please® Paclitaxel Eluting Balloon Catheter At A Very Long-Term Follow-Up
Authors: Ignacio Sanchez-Perez, Alfonso Jurado-Roman, Fernando Lozano, Natalia Pinilla-Echeverri, Maria T. Lopez-Lluva, Manuel Marina-Breysse, Andrea Moreno-Arciniegas
Journal: Journal of the American College of Cardiology (2015)
BAALC and WT1 Transcript Amount Discriminates Secondary or Reactive Eosinophilia from Idiopathic Hypereosinophilic Syndrome or Chronic Eosinophilic Leukemia
Authors: Jiannong Cen, Zixing Chen, Xiaofei Qi, Li Yao, Jun He, Qiaocheng Qiu, Huiyin Qiu
Journal: Blood (2008)
Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group
Authors: A. Gronchi, S. Stacchiotti, P. Verderio, S. Ferrari, J. Martin Broto, A. Lopez-Pousa, A. Llombart-Bosch, A.P. Dei Tos, P. Collini, J.C.r.u.z. Jurado, A. De Paoli, D.M. Donati, A. Poveda, V. Quagliuolo, A. Comandone, G. Grignani, C. Morosi, A. Messina, R. De Sanctis, S. Bottelli, E. Palassini, P.G. Casali, P.i.e.r.o. Picci
Journal: Annals of Oncology (2016)
Editor in chief’s reply to Ebrahim and Davey Smith
Authors: Fiona Godlee
Journal: BMJ (2016)

I congratulate Ebrahim and Davey Smith for changing their minds in response to new information.1 2 I look forward to having the chance to do the same when the anonymised individual patient data (IPD) and clinical study reports (CSRs) from the statin trials are made available for independent review. This is what I have asked the chief medical officer to make happen.3

Your Cochrane …
TCT-423 Effect of left versus right radial artery approach to coronary angiography on radiation exposure in patients with predictors of transradial artery access failure
Authors: Binita Shah, Joseph Burdowski, Yu Guo, Bryan Velez de Villa, Andrew Huynh, Meena Farid, Mansi Maini, Claudia Serrano-Gomez, Arzhang Fallahi, Cezar S. Staniloae, Michael Attubato, Frederick Feit, James Slater, John Coppola
Journal: Journal of the American College of Cardiology (2015)
Clinical Features and Outcome of 148 Patients with Acute Promyelocytic Leukemia in Brazil.
Authors: Rafael H. Jácomo, Raul Melo, Fernanda Souto, Éderson Mattos, Claudia Oliveira, Evandro Fagundes, Rosane Bittencourt, Teresa Bortolheiro, Eduardo Paton, Rodrigo Bendlin, Sebastião Ismael, Maria de Lourdes Chauffaille, Dirceu Silva, Raul Ribeiro, Eduardo M. Rego
Journal: Blood (2006)
TCT-646 Myocardial Injury Following Transaortic Versus Transapical Transcatheter Aortic Valve Replacement
Authors: Henrique B. Ribeiro, Abdellaziz Dahou, Marina Urena, Siamak Mohammadi, Daniel Doyle, Ricardo Allende, Ignacio J. Amat-Santos, Jean-Michel Paradis, Robert DeLarochellière, Rishi Puri, Omar Abdul-Jawad Altisent, Maria Del Trigo, Francisco Campelo-Parada, Philippe Pibarot, Eric Dumont, Josep Rodes-Cabau
Journal: Journal of the American College of Cardiology (2015)
Biomarkers in NOA-04: another piece to the puzzle
Authors: Andrew B. Lassman, Timothy F. Cloughesy
Journal: Neuro-Oncology (2016)

Molecular analyses are now integral to the diagnosis of lowergrade (World Health Organization [WHO] grades II-III) diffuse gliomas, with 3 biologically distinct and prognostic subgroups.From least to most aggressive, as promulgated by the WHO, they include tumors with (i) both isocitrate dehydrogenase (IDH) mutation and chromosome 1p19q codeletion (which occurs exclusively in the context of IDH1 or IDH2 mutation), (ii) IDH mutation but no codeletion, or (iii) wild-type IDH. 1 Long-term follow-up results from a recently updated randomized phase III trial in anaplastic (WHO grade III) gliomas, published in this issue of Neuro-Oncology, 2 also demonstrated the prognostic power of biomarkers.This analysis is of the NOA-04 trial, from the Neuro-Oncology Working Group of the German Cancer Society, classified tumors in a manner similar to the WHO system outlined above.However, based on earlier work, and recognizing that IDH mutation induces the glioma CpG island methylator phenotype (G-CIMP), 3 Wick et al instead characterized tumors as (i) "CIMP codel ", (ii) "CIMP non-codel ," or (iii) "CIMP neg " using epigenome-wide DNA methylation and copynumber profiles. 4These 3 groups are related but not identical to those defined strictly by IDH mutation and 1p19q deletion.For example, IDH wild-type tumors were predominantly but not always classified as CIMP neg .Others similarly reported occasional discordance between IDH mutation and CIMP, 5 suggesting that IDH mutation is sufficient but not necessary to drive CpG island methylation.The CIMP-based classification used in NOA-04 represents a scientific advance.It was clearly prognostic, 2 more so than traditional histology, 2 and has the advantage of reflecting the mechanistic effects of IDH mutation.However, the practical implementation across various health care settings would favor the incorporation of IDH mutation itself as the classifier at present.Although prognostic, no biomarker group predicted benefit from a specific treatment in NOA-04 in which patients were randomized at diagnosis to treatment with either chemotherapy (CT) or radiotherapy (RT) and crossed over to the other modality at disease progression.CT was also randomized between temozolomide and PCV (procarbazine, lomustine (CCNU), and vincristine).Updated results of the primary analysis confirmed
Gemtuzumab Ozogamicin (GO) in Infants with Acute Myeloid Leukemia (AML) – Combined Results from the Children’s Oncology Group (COG) Trials, AAML03P1 and AAML0531
Authors: Erin M. Guest, Richard Aplenc, Lillian Sung, Susana C. Raimondi, Betsy A. Hirsch, Todd A. Alonzo, Robert B. Gerbing, Yi-Cheng Wang, Samir B. Kahwash, Amy Heerema-McKenney, Soheil Meshinchi, Alan S. Gamis
Journal: Blood (2014)
Low Mortality In Sickle Cell Patient Cohort with Elevated Tricuspid Regurgitant Jet Flow Velocity
Authors: Eduard J. Beers van, Charlotte F.J. Tuijn, Erfan Nur, Anita W. Rijneveld, M. R. Mac Gillavry, Ashley Duits, Dees P Brandjes, John-John Schnog, Bart J. Biemond
Journal: Blood (2010)
Surviving Host CD4+CD25+Foxp3+ Cells Following Ablative Conditioning Expand and Comprise the Major Component of the Treg Compartment during the Lymphoid Reconstitution Period Following HCT.
Authors: Allison L. Bayer, Monica Jones, Maite Urbieta, Jackeline Chirinos, Taylor Schreiber, Leslie De Armas, Thomas R. Malek, Robert B. Levy
Journal: Blood (2007)
Rapid Remission Induction by VTD (Velcade, Thalidomide, Dexamethason) in Patients with Multiple Myeloma and High Tumor Burden at Diagnosis.
Authors: Viktoria Odelga, Jutta Ackermann, Verena Sagaster, Hannes Kaufmann, Christoph Zielinski, Johannes Drach
Journal: Blood (2007)